A novel murine T-cell receptor targeting NY-ESO-1

Journal of Immunotherapy

Volumn 37, Issue 3, 2014, Pages 135-146

  Rosati, Shannon F ^a   Parkhurst, Maria R ^a   Hong, Young ^a   Zheng, Zhili ^a   Feldman, Steven A ^a   Rao, Mahadev ^a   Abate Daga, Daniel ^a   Beard, Rachel E ^a   Xu, Hui ^a   Black, Mary A ^a   Robbins, Paul F ^a   Schrump, David A ^a   Rosenberg, Steven A ^a   Morgan, Richard A ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BLUEBIRD BIO   (United States)

Author keywords

cancer testis antigens; epigenetics; immunotherapy; NY ESO 1; synovial cell sarcoma; TCR

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; NY ESO 1 ANTIGEN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELLS, CULTURED; HLA-A2 ANTIGEN; HUMANS; LEUKOCYTES, MONONUCLEAR; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; SPLEEN;

EID: 84896398249     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000019     Document Type: Article

References (33)

1. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550-4557.
2. Goff SL, Smith FO, Klapper JA, et al. J Immunother. 2010;33: 840-847.
3. Chen YT, Scanlan MJ, Sahin U. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94: 1914-1918.
4. Scanlan MJ, Gure AO, Jungbluth AA, et al. Cancer/testis antigens: an expanding family of targets for cancer immuno-therapy. Immunol Rev. 2002;188:22-32.
5. Jager E, Chen YT, Drijfhout JW. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1:definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp. 1998;187:265-270.
6. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917-924.
7. Van Loenen MM, de Boer R, Amir AL, et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. PNAS. 2010;107:10972-10977.
8. Bendle GM, Linnemann C, Hooijkaas AI, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010;16:565-570.
9. Cohen CJ, Zhao Y, Zheng Z, et al. Enhanced antitumor activity of murine-human hybrid T cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 2006;66:8878-8886.
10. Weiser TS, Guo ZS, Ohnmacht GA, et al. Sequential 5-aza-2-deoxycytidine- depsipeptide FR901228 treatment induces apop-tosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother. 2001;24:151-161.
11. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics. 1985;21:235-246.
12. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. Immunology. 1989;142:3714-3725.
13. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114:535-546.
14. Chinnasamy N, Wargo JA, Yu Z, et al. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several type of cancer. J Immunol. 2013;36:133-151.
15. Zhao Y, Zheng Z, Cohen CJ, et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther. 2006;13:151-159.
16. Parkhurst MR, Joo J, Riley JP, et al. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res. 2009;15:169-180.
17. Rao M, Chinnasamy N, Hong JA, et al. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res. 2011;71:4192-4204.
18. Kemp CD, Rao M, Xi S, et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res. 2012;18:77-90.
19. Lai JP, Rosenberg AZ, Miettinen MM, et al. NY-ESO-1 expression in sarcomas: a diagnostic marker and immunother-apy target. Oncoimmunology. 2012;1:1409-1410.
20. Ademuyiwa FO, Bshara W, Attwood K, et al. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS One. 2012;7:e38783.
21. Xu H, Gu N, Liu ZB, et al. NY-ESO-1 expression in hepatocellular carcinoma: a potential new marker for early recurrence after surgery. Oncol Lett. 2012;3:39-44.
22. Dyrskjøt L, Zieger K, Kissow Lildal T, et al. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer. 2012;107:116-122.
23. Kim SH, Lee S, Lee CH, et al. Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung. 2009;187:401-411.
24. Leisegang M, Engels B, Meyerhuber P, et al. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med. 2008;86:573-583.
25. Goff SL, Johnson LA, Black MA, et al. Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1 reactive T cell receptor following a rapid expansion. Cancer Immunol Immunother. 2010;59:1551-1560.
26. Robbins PF, Li YF, El-Gamil Y, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol. 2008;180:6116-6131.
27. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397-411.
28. Krishnadas DK, Shapiro T, Lucas K. Complete remission following decitabine/dendritic cell vaccine for relapsed neuro-blastoma. Pediatrics. 2013;131:e336-e341.
29. Pollack SM, Li Y, Blaisdell MJ, et al. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondro-sarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One. 2012;7:e32165.
30. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, et al. The DNA demethylating agent 5-aza-2-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. 2010;34:899-905.
31. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19:620-626.
32. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36:133-151.
33. Davis J, Theoret MR, Zheng Z, et al. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin Cancer Res. 2010;16:5852-5861.